http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105311645-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2015-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105311645-B |
| titleOfInvention | Application of the embryo FYN related substrates EFS in prevention and treatment enterovirns type 71 infection |
| abstract | It is novel targets and the application of a kind of anti-enterovirns type 71 infection the present invention relates to field of biomedicine technology.The present invention is using Human Brain Microvascular Endothelial (HBMEC) as target cell; the expression of target cell host protein is lowered using RNA perturbation technique; to find the host factor that EV71 infection Human Brain Microvascular Endothelial (HBMEC) can be effectively suppressed; to protect the function of blood-brain barrier, pre- anti-virus passes through blood-brain barrier and infects central nervous system.The present invention is found through experiments that embryo's FYN related substrates EFS (Embryonal FYN-associated substrate) molecule plays an important role in EV71 infection HBMEC, lowers the expression of EFS, can obviously inhibit the infection of EV71.The present invention provides application of the EFS in preparation prevention or treatment enterovirns type 71 infection medicine. |
| priorityDate | 2015-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.